Monitor for COVID-19 vaccine resistance evolution during clinical trials
David Kennedy, Andrew F. Read
Abstract
Although less common than the evolution of antimicrobial drug resistance, vaccine resistance can and has evolved. How likely is it that COVID-19 vaccines currently in development will be undermined by viral evolution? We argue that this can be determined by repurposing samples that are already being collected as part of clinical trials. Such information would be useful for prioritizing investment among candidate vaccines and maximizing the potential long-term impact of COVID-19 vaccines.
Topics & Concepts
BiologyRepurposingCoronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakVirologyDrug resistanceSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Experimental evolutionClinical trialAntibiotic resistanceResistance (ecology)Computational biologyBioinformaticsGeneticsInfectious disease (medical specialty)AntibioticsDiseaseMedicineOutbreakPathologyGeneEcologySARS-CoV-2 and COVID-19 ResearchPneumonia and Respiratory InfectionsBacterial Infections and Vaccines